Can a common antibiotic shield blood cancer patients from deadly infections?
NCT ID NCT03594149
Summary
This study tested whether giving the antibiotic levofloxacin could prevent serious infections in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who were receiving azacitidine treatment. Researchers compared 60 patients who either received the preventive antibiotic or received standard care without preventive antibiotics. The goal was to see if this approach reduced fever episodes requiring hospitalization during the first three treatment cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Lille
Lille, 59037, France
-
CHU Amiens
Amiens, 80000, France
-
CHU Caen
Caen, 14033, France
-
Centre Henri Becquerel
Rouen, 76000, France
Conditions
Explore the condition pages connected to this study.